Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005 | Hematology Meeting Reports (formerly Haematologica Reports)

Current Issue

Vol. 1 No. 8

29 May 2009

View this Issue

Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005

Published: 29 May 2009

Articles

Thalassemia: the continued challenge

DG Nathan

https://doi.org/10.4081/hmr.v1i8.272

165

PDF: 769
- PDF
Deferasirox (ICL670): from bench to bedside

DG Alberti

https://doi.org/10.4081/hmr.v1i8.273

247

PDF: 678
- PDF
ICL670: clinical outcome

MD Cappellini

https://doi.org/10.4081/hmr.v1i8.274

161

PDF: 316
- PDF
Treatment of aggressive lymphoma

Christer Gisselbrecht

https://doi.org/10.4081/hmr.v1i8.275

156

PDF: 188
- PDF
Gemtuzumab ozogamicin

S.L. Amadori

https://doi.org/10.4081/hmr.v1i8.276

166

PDF: 164
- PDF
Imatinib – an overview

MVN Deininger

https://doi.org/10.4081/hmr.v1i8.277

464

PDF: 4396
- PDF
SKI-606 and beyond

DH Boschelli, F Boschelli, B Wu, F Ye, Y Wang, JM Golas, T Young, J Lucas

https://doi.org/10.4081/hmr.v1i8.278

218

PDF: 455
- PDF
Follicular lymphomas

P Solal-Celigny

https://doi.org/10.4081/hmr.v1i8.279

149

PDF: 243
- PDF
Anti-CD80 monoclonal antibody: galiximab

MS Czuczman

https://doi.org/10.4081/hmr.v1i8.280

193

PDF: 1242
- PDF
CD30: a suitable target for immunotherapy?

Paola Borchmann

https://doi.org/10.4081/hmr.v1i8.281

173

PDF: 479
- PDF
Palifermin (Kepivance™) in the treatment of mucositis

Christer Emmanouilides

https://doi.org/10.4081/hmr.v1i8.282

191

PDF: 361
- PDF
Combinations of biological agents in non-Hodgkin’s lymphomas

BD Cheson

https://doi.org/10.4081/hmr.v1i8.283

155

PDF: 263
- PDF
Chronic lymphocytic leukemia

MS Gentile, A Guarini, FR Mauro, R Foà

https://doi.org/10.4081/hmr.v1i8.284

195

PDF: 390
- PDF
Bcr-abl peptides for chronic myeloid leukemia

MS Bocchia, M Ippoliti, MT Pirrotta, E Abruzzese, MM Trawinska, F Forconi

https://doi.org/10.4081/hmr.v1i8.285

200

PDF: 448
- PDF
Tumor idyotipe as target antigen for multiple myeloma

A.B. Curti

https://doi.org/10.4081/hmr.v1i8.286

157

PDF: 291
- PDF
Augmenting anti-tumor efficacy of adoptive immunotherapy with marrow infiltrating lymphocytes

I Borrello

https://doi.org/10.4081/hmr.v1i8.287

145

PDF: 191
- PDF
Bortezomib therapy for refractory/relapsed multiple myeloma

M Cavo

https://doi.org/10.4081/hmr.v1i8.288

179

PDF: 175
- PDF
Ubiquitin-proteasome system is a sensitive target in Ph+ leukemia

G Martinelli, D Cilloni, G Rosti, P Piccaluga, M Rondoni, C Bosi, S Paolini, F Pane, M Amabile, G Nadali, B Izzo

https://doi.org/10.4081/hmr.v1i8.289

216

PDF: 272
- PDF
Bortezomib in lymphoma

A Goy

https://doi.org/10.4081/hmr.v1i8.290

146

PDF: 147
- PDF
Beyond bortezomib alone: combination therapy and new strategies in targeting the proteasome

PG Richardson

https://doi.org/10.4081/hmr.v1i8.291

166

PDF: 248

Untitled: 0
- PDF
Thalidomide analogs

P Tosi, E Zamagni, D Cangini, P Tacchetti, G Perrone, M Ceccolini, M Cavo

https://doi.org/10.4081/hmr.v1i8.292

200

PDF: 510
- PDF
Tipifarnib in hematologic malignancies

J-L Harousseau

https://doi.org/10.4081/hmr.v1i8.293

160

PDF: 304
- PDF
Direct and indirect antitumor activity of zoledronic acid

M Massaia, S Mariani, F Pantaleoni, M Muraro, S Peola, SY Hwang, B Castella, G Matta

https://doi.org/10.4081/hmr.v1i8.294

235

PDF: 298
- PDF
MLN518 – an overview

MVN Deininger

https://doi.org/10.4081/hmr.v1i8.295

285

PDF: 313
- PDF
Activity of the histone deacetylase inhibitors LBH589 and LAQ824 in hematologic malignancies

K Bhalla

https://doi.org/10.4081/hmr.v1i8.296

218

PDF: 346
- PDF
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in heavily pretreated patients with hematological malignancies

OA O’Connor

https://doi.org/10.4081/hmr.v1i8.297

374

PDF: 478
- PDF
Anti-tumor activity of CCI-779 in relapsed mantle cell lymphoma

SM Ansell, SM Geyer, PJ Kurtin, KM Rowland, PJ Flynn, RF Morton

https://doi.org/10.4081/hmr.v1i8.298

218

PDF: 416
- PDF
Gemcitabine: from solid tumor to hematology?

PL Zinzani, M Tani, V Stefoni, E Marchi, M Fina, L Alinari

https://doi.org/10.4081/hmr.v1i8.299

167

PDF: 420
- PDF
The developing role of clofarabine in acute leukemias

S Faderl

https://doi.org/10.4081/hmr.v1i8.300

171

PDF: 254
- PDF
Oral fludarabine

GEG Verhoef

https://doi.org/10.4081/hmr.v1i8.301

146

PDF: 415
- PDF
Oxaliplatin in lymphoma

C Haioun

https://doi.org/10.4081/hmr.v1i8.302

152

PDF: 856
- PDF
Lymphomatous meningitis

C Hatton

https://doi.org/10.4081/hmr.v1i8.303

416

PDF: 2834
- PDF

© PAGEPress 2008-2025 • PAGEPress^® is a registered trademark property of PAGEPress srl, Italy • VAT: IT02125780185 • Privacy